Date: Tuesday 31st March 2020 Time: 14:00 - 15:00 UK Time Speakers: Ketil Tvermosegaard (GSK).
To register for this event, please click here.
This webinar is free for PSI Members and Non-Members.
Label-based flow cytometry allows the quantification of target features of interest by attaching fluorophores (labels) to antibodies and measuring the resulting fluorescence at the relevant wavelengths. This is widely used for cell sorting, i.e., determining cell types.
Image flow cytometry is a technology which enables single cell images in cell sorting experiments. Problematically, directly using this data for classification involves manual inspection of many thousands of images. This creates a bottleneck for analysis and scalability.
As part of an epithelial barrier project; a Medium Throughput screen was conducted to investigate whether candidate CRISPR gene knockouts modulated the proportion of cells which differentiated into ciliated cells (important for indications such as COPD and asthma).
However, the team hypothesized that traditional label-based flow cytometry did not always properly classify cell types. We were approached about developing a scalable way of using image flow cytometry for determining whether cells are ciliated. This would provide them with an alternative endpoint and a way to test their hypothesis.
In this project, we;
1) Developed Python code to extract images from the proprietary file format
2) Built a proof-of-concept convolutional neural network. Results here suggested the problem was solvable with Deep Learning
3) Initiated a Tessella Analytics Partnership project with Tessella
4) Worked with Tessella to steer their development of an appropriate architecture for the neural network, which achieved better-than-human performance
5) Applied the trained network to a validation screen and confirmed disagreements between label-based and label-free flow cytometry.
Visualising the drug harm profile in Randomised Controlled Trials – A Consensus of UK trial researchers
The UKCRC CTU statisticians’ operations group in collaboration with Imperial College London are hosting a one-day consensus meeting to develop recommendations to support researchers in their choice of visualisations for adverse event data in RCT publications.
PSI Webinar: How can PSI, “a community dedicated to leading and promoting the use of statistics within the healthcare industries for the benefit of patients”, help you be more successful in your career?
Have you ever wondered what it takes to be successful as a statistician or data scientist in the healthcare/pharma industry and what can give you the extra edge to develop your career? Come and listen to these industry leaders views on how to be successful and the advantages of being part of the PSI community.
PSI Journal Club: Progressing Phase II Data into Phase III
Our next journal club features two papers on the topic of Progressing Phase II Data into Phase III, held on the 23rd April 2020 from 4-5pm BST. Please join us to hear Haolun Shi (Simon Fraser University, Burnaby) and Daniele De Martini (Università degli Studi di Milano‐Bicocca, Milan) present their recent work. The webinar will be chaired by Andy Grieve (UCB).
The ITIT course will take 25 delegates new to the industry on a complete drug development experience from discovery to marketing. They will visit 6 companies from October 2020 to July 2021 to learn about 6 topics from experts in their field. The ITIT course will have 3 sessions in continental Europe and 3 - 4 sessions in the UK. It promises to be a truly memorable course.
This course is aimed at Statisticians and Programmers experienced in SAS, but little or no experience with R.
An Introduction to R studio and the R language, statistical graphics, programming statistical models, simulations and more…
PSI Toxicology SIG workshop – 24th and 25th November 2020
The Toxicology SIG provides a forum for statisticians working in regulatory/investigative toxicology, as well as most other pre-clinical areas, to discuss issues and interact with one another.
This 1.5-day workshop will involve approximately 20 statisticians, focusing on discussions around “best practice” in the statistical analysis of various data types.
The afternoon of Day 1 will include a 4.5 hour Bayesian training course focused towards applications in toxicology/pre-clinical, provided by Prof. Dr. Katja Ickstadt and is included in the workshop fee.
The cost will be £270 including VAT per delegate, inclusive of food and one night’s accommodation (and the training course). The workshop is being held at the Crowne Plaza Hotel, Heathrow.
The agenda and topics that will be discussed are yet to be finalised, but please get in touch with firstname.lastname@example.org if you have suggestions. Full details will be circulated in the coming weeks.
Statistical Director for Health Technology Assessment in Biostatistics
Global pharma company Novo Nordisk are right now looking for a Statistical Director to drive the Health Technology Assessment agenda in the Biostatistical Centre of Expertise in their office just outside Copenhagen.